PatentSight is proud to announce that our patent analytics software is now a patent protected Intellectual Property. In August, 2019, the USPTO officially granted Nils Omland, our founder and CEO, with a patent for the PatentSight Business Intelligence software solution. Back in 2018, when LexisNexis® acquired PatentSight, this patent was still undergoing review. The granting of this patent makes our SaaS offering, officially, one of its kind.
In September 2016, the German drugs and chemicals group Bayer announced its intention to acquire the multinational Monsanto, known for its Roundup herbicide and GMOs. This merger would produce the world’s most powerful company in the seed and pesticide industry. On 21 March 2018 the EU commission released a Press Release announcing their approval of the acquisition of Monsanto by Bayer. The merger was approved on the conditional divestiture of an extensive remedy package, which addresses the parties' overlaps in seeds, pesticides and digital agriculture. It is for determining such inconspicuous aspects of a merger, like technology overlap, that the EU commission relied on the LexisNexis® PatentSight® database and our award-winning Business Intelligence software solution.
From recent news reports it became clear that China accounts for almost 90% of the world’s production and supply of the so-called Rare Earth Elements (REE). These are a group of 17 elements that are not commonly found in the earth's surface. For e.g. Scandium, one of the rare earth elements, is heavily used in manufacturing parts for the aerospace industry. Similarly, these elements have varied and extremely specific uses, for which, at least for the time-being, no viable substitutes can be sourced. We used our excellent patent database and scientifically proven metrics to analyze the current situation around rare earth elements from a patent quality point of view to identify possible opportunities and threats in this business.
Recently, we applied the PatentSight Patent Asset Index methodology to gain a new insight into which of Israel’s research bodies are leading in innovation. The index assesses the strength of an organization’s patent portfolio in terms of quality of patents held measured by TechnologyRelevance™ and Market Coverage ™. So, what did we find?
In January of this year, U.S. pharmaceutical manufacturers Bristol-Myers Squibb (BMS) and Celgene Corporation announced they had entered into a definitive merger agreement for BMS to acquire Celgene.
The stated aim of the merger is to create ‘a premier innovative biopharma company’ with a particular focus on building an expanded offering in the cancer and immunotherapy space. If completed, the transaction is expected to cost $74 billion in a cash and stock deal, whereby Celgene shareholders will receive 1.0 BMS share as well as $50 in cash for each share of Celgene.
Our analysis of the two firms’ respective patent portfolios provides insight into how this merger would affect the U.S. pharma market. For this analysis, we employed our Patent Asset IndexTM methodology, which scientifically assesses patent families against Key Performance Indicators of Technology RelevanceTM and Market CoverageTM.
For a study commissioned by IAM, PatentSight has taken a closer look at the patenting activity of leading universities and research centers based on the Patent Asset IndexTM.
Today, LexisNexis published a ranking of China’s top 20 most innovative universities based on their patent assets. Analysts at LexisNexis have identified these top universities as sorted by the Patent Asset Index™.
You may have seen our recent press release but I wanted to personally express my excitement over the recent acquisition by LexisNexis® IP. We anticipate that as a result of this acquisition, we will be able to make significant enhancements to our product.
With added content, financial resources, and a broader customer base we will significantly accelerate our development. In particular, the advent of powerful self-learning algorithms often described as “artificial intelligence” is a great opportunity to reach the next breakthrough in patent analytics. We are thrilled to leverage our competence in high quality data and reliable science-based algorithms to continue leading the field with advanced tools that offer unique and reliable business insights.
Rest assured, many things you value about PatentSight will not change. PatentSight will continue under the leadership of myself and my team in the same offices in Bonn, Germany. All PatentSight employees will be retained and your current points of contact will not change. Our much-praised Consulting & Support Team will continue to serve you directly. The name of the product will change slightly to LexisNexis PatentSight.
We look forward to our continued relationship. Please contact me, Björn Ulmer or your main contact in the business development team if you have any additional questions.